Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05346354 · ClinicalTrials.gov registry record · Phase 2

Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD

A Phase 2 study of Neuromyelitis Optica Spectrum Disorder, sponsored by Alexion Pharmaceuticals.

Recruiting
Registry status
Phase 2
Development phase
12
Enrollment target
20
Study locations

NCT05346354 is a Phase 2 study of Neuromyelitis Optica Spectrum Disorder that is actively recruiting participants, run by Alexion Pharmaceuticals. The registered enrollment target is 12 participants, below the 65-participant average among 6 other Neuromyelitis Optica Spectrum Disorder trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05346354, a Phase 2 study of Neuromyelitis Optica Spectrum Disorder, is actively recruiting participants, sponsored by Alexion Pharmaceuticals.

RECRUITING
Registry status
Phase 2
Development phase
12 participants
Enrollment target
20
Study locations

Study Summary

The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab in pediatric participants with Neuromyelitis Optica Spectrum Disorder (NMOSD).

Conditions Studied

Neuromyelitis Optica Spectrum Disorder

Interventions

  • DRUG Ravulizumab

Study Locations (20)

Other

  • Research Site - Le Kremlin-Bicêtre
  • Research Site - Marseille
  • Research Site - Montpellier
  • Research Site - Bochum
  • Research Site - Giessen
  • Research Site - Catania
  • Research Site - Chieti
  • Research Site - Gallarate
  • Research Site - Roma
  • Research Site - Yokohama
  • Research Site - Goyang-si

District of Columbia

  • Research Site - Washington D.C.

Florida

  • Research Site - Miami

Massachusetts

  • Research Site - Boston

Missouri

  • Research Site - St Louis

North Carolina

  • Research Site - Durham

Pennsylvania

  • Research Site - Philadelphia

Alberta

  • Research Site - Edmonton

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2022-06-23
Est. Completion 2029-04-02
Phase Phase 2

Sponsor

Alexion Pharmaceuticals

162 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05346354

The ClinicalTrials.gov registry entry for NCT05346354 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 65-participant average among 6 other Neuromyelitis Optica Spectrum Disorder trials with a reported enrollment target (82% lower). The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Neuromyelitis Optica Spectrum Disorder appearing as the primary indexed condition, and to 1 intervention - of which Ravulizumab is the first listed.

NCT05346354 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, District of Columbia, Florida.

Frequently Asked Questions

What is clinical trial NCT05346354 about?

NCT05346354 is a clinical study titled "Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD". The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab in pediatric participants with Neuromyelitis Optica Spectrum Disorder (NMOSD).

What is the current status of trial NCT05346354?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2022-06-23. Estimated completion is 2029-04-02.

What conditions does trial NCT05346354 study?

This clinical trial studies the following conditions: Neuromyelitis Optica Spectrum Disorder.

What interventions are being tested in trial NCT05346354?

The interventions under investigation include: Ravulizumab (DRUG).

Who is sponsoring clinical trial NCT05346354?

This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05346354 being conducted?

This trial has 20 study locations across District of Columbia, Florida, Massachusetts, Missouri, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neuromyelitis Optica Spectrum Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neuromyelitis Optica Spectrum Disorder

All registered trials for this condition

District of Columbia

All trials with a study site in District of Columbia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.